<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163759</url>
  </required_header>
  <id_info>
    <org_study_id>GA28948</org_study_id>
    <secondary_id>2013-004279-11</secondary_id>
    <nct_id>NCT02163759</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)</brief_title>
  <acronym>HIBISCUS I</acronym>
  <official_title>Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This Phase III, double blind, placebo and active comparator controlled, multicenter study
      will investigate the efficacy and safety of etrolizumab in induction of remission in
      participants with moderately to severely active UC who are naIve to TNF inhibitors and
      refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 4, 2014</start_date>
  <completion_date type="Actual">March 19, 2020</completion_date>
  <primary_completion_date type="Actual">February 19, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Induction of Remission With Etrolizumab Compared With Placebo at Week 10, as Determined by the Mayo Clinic Score (MCS)</measure>
    <time_frame>Week 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Induction of Remission With Etrolizumab Compared With Adalimumab at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Induction of Clinical Remission at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Week 10, as Determined by the MCS</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement in Endoscopic Appearance of the Mucosa at Week 10, as Determined by the Mayo Endoscopic Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Endoscopic Remission at Week 10, as Determined by the Mayo Endoscopic Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Remission at Week 10 and who Maintained Remission to Week 14, as Determined by the MCS</measure>
    <time_frame>Week 10 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Histological Remission at Week 10, as Determined by the Nancy Histological Subscore</measure>
    <time_frame>Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MCS Rectal Bleeding Subscore at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MCS Stool Frequency Subscore at Week 6</measure>
    <time_frame>Baseline, Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ulcerative Colitis (UC) Bowel Movement Signs and Symptoms at Week 10, as Assessed by UC-Participant-Reported Outcome Signs and Symptoms (PRO/SS)</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in UC Abdominal Symptoms at Week 10, as Assessed by UC-PRO/SS</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-Related Quality of Life (QOL) at Week 10, as Assessed by Overall Inflammatory Bowel Disease Questionnaire (IBDQ)</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Etrolizumab: Serum Concentration</measure>
    <time_frame>Pre-dose (0 hour) on Day 1, Week 10, Week 14, early termination/end of safety follow-up (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event by Severity, According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0)</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Serious Adverse Event</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events Leading To Study Drug Discontinuation</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Infection-Related Adverse Events by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Infection-Related Adverse Events</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Injection-Site Reactions by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Hypersensitivity Reaction Events by Severity, According to NCI CTCAE v4.0</measure>
    <time_frame>Baseline up to end of study (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Anti-Therapeutic Antibodies (ATA) to Etrolizumab</measure>
    <time_frame>Pre-dose (0 hour) on Day 1, Week 4, Week 10, Week 14, early termination/end of safety follow-up (up to Week 26)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Laboratory Abnormalities</measure>
    <time_frame>Baseline (Day 1), Week 10, and any unscheduled visits or early withdrawal from treatment, up to end of study (up to Week 26)</time_frame>
    <description>Laboratory parameters for hematology, blood chemistry, and urinalysis will be measured compared with a standard reference range. Values outside the standard reference range are considered abnormalities. Not every laboratory abnormality qualifies as an adverse event. A laboratory test result must be reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment or a medical intervention; or is clinically significant in the investigator's judgment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">358</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive adalimumab up to Week 8 and placebo matching to etrolizumab up to Week 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo matching to etrolizumab up to Week 12 and placebo matching to adalimumab up to Week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.</description>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Adalimumab Placebo</intervention_name>
    <description>Placebo matching to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.</description>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrolizumab</intervention_name>
    <description>Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).</description>
    <arm_group_label>Etrolizumab + Adalimumab Placebo</arm_group_label>
    <other_name>PRO145223</other_name>
    <other_name>RO5490261</other_name>
    <other_name>RG7413</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Etrolizumab Placebo</intervention_name>
    <description>Placebo matching to etrolizumab will be administered SC Q4W.</description>
    <arm_group_label>Adalimumab + Etrolizumab Placebo</arm_group_label>
    <arm_group_label>Etrolizumab Placebo + Adalimumab Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of UC established at least 3 months prior to randomization (Day 1)

          -  Moderately to severely active UC as determined by the MCS

          -  Naive to treatment with TNF inhibitor therapy

          -  An inadequate response, loss of response, or intolerance to prior corticosteroid
             and/or immunosuppressant treatment

          -  Background UC therapy may include oral 5-aminosalisylate (5-ASA), budesonide, oral
             corticosteroids, probiotics, azathioprine (AZA), 6-mercaptopurine (6MP), or
             methotrexate (MTX) if doses have been stable for:

          -  AZA, 6-MP, MTX: 8 weeks immediately prior to randomization

          -  5-ASA: 4 weeks immediately prior to randomization

          -  Corticosteroids: 4 weeks immediately prior to randomization; if corticosteroids are
             being tapered, dose has to be stable for at least 2 weeks prior to randomization

          -  Use of highly effective contraception method as defined by the protocol

          -  Have received a colonoscopy within the past year or be willing to undergo a
             colonoscopy in lieu of a flexible sigmoidoscopy at screening

        Exclusion Criteria:

        Exclusion Criteria Related to Inflammatory Bowel Disease:

          -  Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for
             UC

          -  Past or present ileostomy or colostomy

          -  Diagnosis of indeterminate colitis

          -  Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

          -  Diagnosis of toxic megacolon within 12 months of initial screening visit

          -  Any diagnosis of Crohn's disease

          -  Past or present fistula or abdominal abscess

          -  A history or current evidence of colonic mucosal dysplasia

          -  Patients with any stricture (stenosis) of the colon

          -  Patients with history or evidence of adenomatous colonic polyps that have not been
             removed

        Exclusion Criteria Related to Prior or Concomitant Therapy:

          -  Prior treatment with TNF-alpha antagonists

          -  Any prior treatment with etrolizumab or other anti integrin agents

          -  Any prior treatment with rituximab

          -  Any treatment with tofacitinib during screening

          -  Any prior treatment with anti-adhesion molecules

          -  Use of IV steroids within 30 days prior to screening with the exception of a single
             administration of IV steroid

          -  Use of agents that deplete B or T cells

          -  Use of anakinra, abatacept, cyclosporine, sirolimus, or mycophenolate mofetil (MMF)
             within 4 weeks prior to randomization

          -  Chronic nonsteroidal anti inflammatory drug (NSAID) use

          -  Patients who are currently using anticoagulants including, but not limited to,
             warfarin, heparin, enoxaparin, dabigatran, apixaban, rivaroxaban

          -  Patients who have received treatment with corticosteroid enemas/suppositories and/or
             topical (rectal) 5 ASA preparations within 2 weeks prior to randomization

          -  Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to randomization

          -  Received any investigational treatment including investigational vaccines within 5
             half lives of the investigational product or 28 days after the last dose, whichever is
             greater, prior to randomization

          -  History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to
             chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or
             hypersensitivity to etrolizumab (active drug substance) or any of the excipients (L
             histidine, L-arginine, succinic acid, polysorbate 20)

          -  Patients administered tube feeding, defined formula diets, or parenteral
             alimentation/nutrition who have not discontinued these treatments within 3 weeks prior
             to randomization

        Exclusion Criteria Related to General Safety:

          -  Pregnant or lactating

          -  Lack of peripheral venous access

          -  Hospitalization (other than for elective reasons) during the screening period

          -  Significant uncontrolled comorbidity, such as cardiac (e.g., moderate to severe heart
             failure New York Heart Association Class III/IV), pulmonary, renal, hepatic,
             endocrine, or gastrointestinal disorders

          -  Neurological conditions or diseases that may interfere with monitoring for PML

          -  History of demyelinating disease

          -  Clinically significant abnormalities on screening neurologic examination (PML
             Objective Checklist)

          -  Clinically significant abnormalities on the screening PML Subjective Checklist

          -  History of alcohol, drug, or chemical abuse less than 6 months prior to screening

          -  Conditions other than UC that could require treatment with &gt; 10 mg/day of prednisone
             (or equivalent) during the course of the study

          -  History of cancer, including hematologic malignancy, solid tumors, and carcinoma in
             situ, within 5 years before screening

        Exclusion Criteria Related to Infection Risk

          -  Congenital or acquired immune deficiency

          -  Patients must undergo screening for HIV and test positive for preliminary and
             confirmatory tests

          -  Positive hepatitis C virus (HCV) antibody test result

          -  Positive hepatitis B virus (HBV) antibody test result

          -  Evidence of or treatment for Clostridium difficile (as assessed by C. difficile toxin
             testing) within 60 days prior to randomization or other intestinal pathogens (as
             assessed by stool culture and ova and parasite evaluation) within 30 days prior to
             randomization

          -  Evidence of or treatment for clinically significant cytomegalovirus (CMV) colitis
             (based on the investigator's judgment) within 60 days prior to randomization

          -  History of active or latent TB

          -  History of recurrent opportunistic infections and/or history of severe disseminated
             viral infections

          -  Any serious opportunistic infection within the last 6 months prior to screening

          -  Any current or recent signs or symptoms (within 4 weeks before screening and during
             screening) of infection

          -  Any major episode of infection requiring treatment with IV antibiotics within 8 weeks
             prior to screening or oral antibiotics within 4 weeks prior to screening

          -  Received a live attenuated vaccine within 4 weeks prior to randomization

          -  History of organ transplant

        Exclusion Criteria Related to Laboratory Abnormalities (at Screening)

          -  Serum creatinine &gt;2 x upper limit of normal (ULN)

          -  ALT or AST &gt; 3 x ULN or alkaline phosphatase &gt; 3 x ULN or total bilirubin &gt; 2.5 x ULN

          -  Platelet count &lt; 100,000/uL

          -  Hemoglobin &lt; 8 g/dL

          -  Absolute neutrophil count &lt; 1500/uL

          -  Absolute lymphocyte count &lt; 500/uL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rocky Mountain Gastroenterology Associates, P.L.L.C.; Gastroenterology</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Gastroenterology</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Group of Naples</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huron Gastroenterology Associates</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research, LLC</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellness Clinical Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Research Institute, LLC</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Medico DAMIC</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bankstown-Lidcombe Hospital</name>
      <address>
        <city>Bankstown</city>
        <state>New South Wales</state>
        <zip>2200</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Hospital Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital; Department of Colorectal Medicine and Genetics</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L2IP - Instituto de Pesquisas Clínicas Ltda.</name>
      <address>
        <city>Brasilia</city>
        <state>DF</state>
        <zip>70200-730</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Goiano de Gastroenterologia e Endoscopia Digestiva Ltda</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74535-170</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Felicio Rocho</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30110-068</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clementino Fraga Filho - UFRJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas - UFRGS</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>SP</state>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sv. Ivan Rilski&quot;, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsaritsa Yoanna - ISUL, EAD</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Medica Plus</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OÜ Innomedica</name>
      <address>
        <city>Tallinn</city>
        <zip>10117</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tallinn Central Hospital</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Estonia Medical Centre Foundation</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy cedex</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nice - Hopital de l'Archet 2</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Etienne - Hôpital Nord</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral en Reumatología S.A. de C.V. (CIRSA)</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jose Tec Salud, Fundación Santos y de la Garza Evia, I.B.P.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium S. de R.L. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr Jose Eleuterio Gonzalez; Universidad Autónoma de Nuevo León</name>
      <address>
        <city>Monterrey</city>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Sw. Lukasza</name>
      <address>
        <city>Częstochowa</city>
        <zip>42-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>7 Szpital Marynarki Wojennej z Przychodnia SPZOZ im. W. Lasinskiego</name>
      <address>
        <city>Gdansk</city>
        <zip>80-305</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Medyczne ProMiMed</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med-Gastr Przychodnia Specjalistyczna</name>
      <address>
        <city>Lodz</city>
        <zip>91-034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska</name>
      <address>
        <city>Lublin</city>
        <zip>20-015</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GASTROMED Sp. z o.o.</name>
      <address>
        <city>Lublin</city>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Specjalistyczny Szpital w Olsztynie</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SOLUMED Centrum Medyczne</name>
      <address>
        <city>Poznań</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczna Praktyka Lekarska Dr med. Marek Horynski; endoskopia</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Twoja Przychodnia-Szczecinskie Centrum Medyczne</name>
      <address>
        <city>Szczecin</city>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Zdrowia MDM</name>
      <address>
        <city>Warszawa</city>
        <zip>00-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im. M. Sklodowskiej Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ars-Medica S.C Rybak Maria, Rybak Zbigniew</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-333</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EMC Instytut Medyczny S.A.</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AppleTreeClinics Sp. z o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yusupov Hospital</name>
      <address>
        <city>Moskva</city>
        <state>Adygeja</state>
        <zip>127015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baltic Medicine</name>
      <address>
        <city>St.Petersburg</city>
        <state>Leningrad</state>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Medical Institution &quot;Evromedservis&quot;</name>
      <address>
        <city>Pushkin</city>
        <state>Sankt Petersburg</state>
        <zip>196603</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;City Multy-field Hospital # 2&quot;; Intensive Pulmonology and Thoracal Surgery</name>
      <address>
        <city>Sankt-peterburg</city>
        <state>Sankt Petersburg</state>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical and Sanitary Division of Severstal</name>
      <address>
        <city>Cherepovets</city>
        <state>Vologda</state>
        <zip>162600</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI HPE Altai State Medical University of MoH and SD; Out-patient Department</name>
      <address>
        <city>Barnaul</city>
        <zip>656038</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBIH Central Clinical Hospital of RAS</name>
      <address>
        <city>Moscow</city>
        <zip>119333</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;State Scientific Centre of Coloproctology&quot; of the MoH of RF; Gastroenterology</name>
      <address>
        <city>Moscow</city>
        <zip>123154</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of NN region &quot;RCH of NN n.a. N.A.Semashko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI of HPE &quot;Omsk SMA&quot; Ministry of healthcare of RF&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SEIHPE &quot;Rostov SMU of MoH of RF&quot;</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital #26</name>
      <address>
        <city>St Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC International Medical Centre &quot;SOGAZ&quot;</name>
      <address>
        <city>St-Petersburg</city>
        <zip>198035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSMEI HPE &quot;Military Medical Academy n.a. S.M.Kirov&quot;of Minist</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Diagnostic Consultative Center</name>
      <address>
        <city>Stavropol</city>
        <zip>355017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Zvezdara</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11040</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Bezanijska Kosa</name>
      <address>
        <city>Belgrade</city>
        <zip>11070</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Zemun</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Djordje Joanovic&quot;; Gastroenterology</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou F.D. Roosevelta</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>974 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnica A.Lena Humenne, n.o.</name>
      <address>
        <city>Humenné</city>
        <zip>066 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management spol. s r.o.</name>
      <address>
        <city>Nitra</city>
        <zip>94901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro I, s.r.o.</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Svet zdravia a.s.</name>
      <address>
        <city>Rimavska Sobota</city>
        <zip>97901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accout Center s.r.o.</name>
      <address>
        <city>Šahy</city>
        <zip>936 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNE Prof. O.O. Shalimov Kharkiv City Clinical Hospital #2 of KCC</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-commercial Enterprise of Kharkiv Regional Council Regional Clinical Hospital</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkiv Governorate</state>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution of Kyiv Regional Council Kyiv Regional Clinical Hospital</name>
      <address>
        <city>Kyiv</city>
        <state>Kharkiv Governorate</state>
        <zip>04107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center of Limited Liability Company Medical Clinic Blagomed</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>1023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI of Kyiv RC Regional Clinical Hospital #2</name>
      <address>
        <city>Kyiv</city>
        <state>KIEV Governorate</state>
        <zip>4073</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI UDH Dept of Ther SHEI Fac of PGE&amp;Pre-Univ Training</name>
      <address>
        <city>Uzhgorod</city>
        <state>KIEV Governorate</state>
        <zip>88009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI City Hospital #1</name>
      <address>
        <city>Zaporizhzhia</city>
        <state>Tavria Okruha</state>
        <zip>69104</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RCI Chernivtsi RCH Gastroenterology Bukovinsky SMU</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI Kharkiv City Clinical Hospital #13</name>
      <address>
        <city>Kharkiv</city>
        <zip>61124</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>02232</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.V. Sklifosovskyi Poltava RCH Outpatient UMSA HSEIU Ukrainian Medical Stomatological Academy</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CI City Hospital #7</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Hong Kong</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2014</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>rhuMAb Beta7</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

